ECSP109851A - Sales de amina de un antagonista de crth2 - Google Patents

Sales de amina de un antagonista de crth2

Info

Publication number
ECSP109851A
ECSP109851A EC2010009851A ECSP109851A ECSP109851A EC SP109851 A ECSP109851 A EC SP109851A EC 2010009851 A EC2010009851 A EC 2010009851A EC SP109851 A ECSP109851 A EC SP109851A EC SP109851 A ECSP109851 A EC SP109851A
Authority
EC
Ecuador
Prior art keywords
salts
amina
crth2 antagonist
crth2
benzamido
Prior art date
Application number
EC2010009851A
Other languages
English (en)
Inventor
Tai Wei Ly
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109851(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of ECSP109851A publication Critical patent/ECSP109851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proveen sales de amina de ácido [(4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil) benzamido) bencil) pirimidin-5-il] acético, procesos para su preparación, composiciones farmacéuticas, que los contienen, y su uso para tratar, prevenir, o aliviar uno o más síntomas de un trastorno o enfermedad mediado por CRTH2.
EC2010009851A 2007-06-21 2010-01-06 Sales de amina de un antagonista de crth2 ECSP109851A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93673607P 2007-06-21 2007-06-21

Publications (1)

Publication Number Publication Date
ECSP109851A true ECSP109851A (es) 2010-03-31

Family

ID=39731477

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009851A ECSP109851A (es) 2007-06-21 2010-01-06 Sales de amina de un antagonista de crth2

Country Status (22)

Country Link
US (1) US8278310B2 (es)
EP (1) EP2176240A1 (es)
JP (1) JP6006914B2 (es)
KR (1) KR20100039350A (es)
CN (4) CN102898380A (es)
AR (1) AR067118A1 (es)
BR (1) BRPI0812597A2 (es)
CA (1) CA2690436A1 (es)
CL (1) CL2008001817A1 (es)
CO (1) CO6251286A2 (es)
EC (1) ECSP109851A (es)
IL (1) IL202755A0 (es)
MA (1) MA31536B1 (es)
MX (1) MX2009013813A (es)
MY (1) MY149005A (es)
NZ (1) NZ581856A (es)
RU (1) RU2468013C2 (es)
TN (1) TN2009000517A1 (es)
TW (1) TWI419693B (es)
UA (1) UA101326C2 (es)
WO (1) WO2008156781A1 (es)
ZA (1) ZA200909110B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
US8541419B2 (en) * 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20120142715A1 (en) 2009-07-06 2012-06-07 Boehringer Ingelheim International Gmbh Polymorph of [4,6-bis(dimethylamino)-2-(4-benzyl)pyrimidin-5-yl]
EP2504318A2 (en) 2009-11-24 2012-10-03 Boehringer Ingelheim International GmbH Crystalline salt forms of a pyrimidin-5-yl acetic acid derivative
EA201200765A1 (ru) 2009-11-24 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2015124168A1 (en) 2014-02-18 2015-08-27 Bekey A/S Controlling access to a location
CA3056590A1 (en) 2017-02-15 2018-08-23 Nanyang Technological University Compounds for treating tuberculosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1280522B1 (en) * 2000-04-26 2004-12-01 Warner-Lambert Company Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
US7078690B2 (en) * 2002-02-04 2006-07-18 Applied Materials, Israel, Ltd. Monitoring of contact hole production
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
AR053046A1 (es) * 2005-04-07 2007-04-18 Teijin Pharma Ltd Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo
US8507005B2 (en) * 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
US8541419B2 (en) * 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists

Also Published As

Publication number Publication date
MY149005A (en) 2013-06-28
CN101772489B (zh) 2013-02-20
EP2176240A1 (en) 2010-04-21
KR20100039350A (ko) 2010-04-15
CL2008001817A1 (es) 2009-03-13
RU2468013C2 (ru) 2012-11-27
MA31536B1 (fr) 2010-07-01
HK1144940A1 (en) 2011-03-18
TW200911261A (en) 2009-03-16
JP6006914B2 (ja) 2016-10-12
CN102898381A (zh) 2013-01-30
CN102875478A (zh) 2013-01-16
NZ581856A (en) 2011-05-27
CN102898380A (zh) 2013-01-30
IL202755A0 (en) 2010-06-30
WO2008156781A1 (en) 2008-12-24
BRPI0812597A2 (pt) 2015-02-18
ZA200909110B (en) 2011-03-30
US20110034482A1 (en) 2011-02-10
UA101326C2 (en) 2013-03-25
RU2010101795A (ru) 2011-07-27
AR067118A1 (es) 2009-09-30
JP2010530426A (ja) 2010-09-09
CN101772489A (zh) 2010-07-07
CO6251286A2 (es) 2011-02-21
MX2009013813A (es) 2010-02-03
CA2690436A1 (en) 2008-12-24
TWI419693B (zh) 2013-12-21
TN2009000517A1 (en) 2011-03-31
US8278310B2 (en) 2012-10-02
AU2008266854A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
ECSP109851A (es) Sales de amina de un antagonista de crth2
ECSP109890A (es) Particulas de un antagonista de crth2
UY32203A (es) Amino pirimidinas y su uso en terapia
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
CR10663A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
BR112012008317A2 (pt) produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
BRPI0817843B8 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
BRPI0707704A8 (pt) derivados de antranilamida / 2-amino-heteroareno carboxamida
MX382569B (es) Compuesto de carboxamida, sulfonamida y amina para trastornos metabolicos.
UY32848A (es) Compuestos heterocíclicos de oxima
BRPI0815360A8 (pt) Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto
CR20110611A (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil) acetato de 4-(dimetilamino)butilo
CR10963A (es) Compuestos de 2-amino pirimidina
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
UY31839A (es) Compuestos
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
AR082659A1 (es) Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CR11665A (es) Farmacoforos duales-antagonistas muscarinicos de pde4
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
AR069009A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina